<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503865</url>
  </required_header>
  <id_info>
    <org_study_id>0103RK00112</org_study_id>
    <nct_id>NCT02503865</nct_id>
  </id_info>
  <brief_title>Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome</brief_title>
  <acronym>DRWMNTMS</acronym>
  <official_title>Phase 1-2 Study of Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nazarbayev University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute Of Cardiology &amp; Internal Diseases, Kazakhstan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nazarbayev University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic syndrome: aetiology, pathogenesis, diagnosis, clinical management and prognosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: To create the complex scientifically proved concept of Metabolic syndrome (МS)
      development based on elaboration of the new methods of clinical diagnostics of МS components
      and highly effective МS clinical management in comparative studying of clinical, laboratory
      and cost effectiveness.

      Participants and methods: This clinical study included 351 adults (184 female) in the
      Scientific research institute of cardiology and internal diseases (Almaty, the Republic of
      Kazakhstan). Statistical analysis was performed using Microsoft Excel-2008 in updating
      Lapach, Chubenko et al (2000) and SPSS for Windows v.17.0.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Glucose Level</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Fasting blood glucose (FBG) (mmole/L) and Two-hour postprandial glucose (THPG) (mmole/L) were measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic/ Diastolic Blood Pressures (mm Hg)</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Systolic and Diastolic Blood Pressures (mm Hg) was measured by manual/automatic tonometery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Blood sample for lipid profile (Cholesterol in mmole/L, High-density Lipoproteids in mmole/L, Triglycerides in mmole/L) was measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoassay Hormones in Blood</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Immunoassay Insulin in the blood (in nU/L) was investigated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoassay Cortisole in Blood</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Immunoassay Cortisole in the blood (nmole/L) was measured</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">351</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Conventional Patient group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Analimentary detoxication&quot; Weight loss</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vegetables and salt diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy people</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>64 healthy people</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin</intervention_name>
    <description>Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day</description>
    <arm_group_label>Conventional Patient group</arm_group_label>
    <other_name>Conventional Patient group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>&quot;Analimentary detoxication&quot;</intervention_name>
    <description>Vegetable and salt diet</description>
    <arm_group_label>&quot;Analimentary detoxication&quot; Weight loss</arm_group_label>
    <other_name>Experimental Patient group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written consent form

          -  age&gt; 25 years

          -  skinfold thickness &gt; 0,7 cm BP&gt; 130/85 mm Hg or a patient on antihypertensive
             medications fasting blood glucose &gt; 6.1 mmole/L, or 2-hour postprandial glucose level
             &gt; 11.1 mmole/L / or a patient with type 2 diabetes blood cholesterol &gt; 5.6 mmole/L
             possibility of treatment &gt; 6 months follow-up &gt; 1 year

        Exclusion Criteria:

          -  complete immobilization of a patient (paresis /paralysis)

          -  patients with severe concomitant diseases of the kidneys and (or) of the liver

          -  early post-operative condition

          -  mental illness

          -  pregnancy

          -  persons who are in prison

          -  persons who are in military Armed Forces
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tabynbayev Nariman, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Nazarbayev University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Republican Scientific Center for Emergency Medicine</name>
      <address>
        <city>Astana</city>
        <zip>010000</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
  </location_countries>
  <link>
    <url>http://www.diabetes.org/food-and-fitness/weight-loss/?referrer=https://www.google.kz/</url>
    <description>Click here for more information about this study: Learn how to lose weight in a healthy way and keep it off. Find the weight loss strategy that works best for you and start feeling better now.</description>
  </link>
  <reference>
    <citation>Penn L, White M, Lindström J, den Boer AT, Blaak E, Eriksson JG, Feskens E, Ilanne-Parikka P, Keinänen-Kiukaanniemi SM, Walker M, Mathers JC, Uusitupa M, Tuomilehto J. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PLoS One. 2013;8(2):e57143. doi: 10.1371/journal.pone.0057143. Epub 2013 Feb 25.</citation>
    <PMID>23451166</PMID>
  </reference>
  <reference>
    <citation>Berk KA, Buijks H, Ozcan B, Van't Spijker A, Busschbach JJ, Sijbrands EJ. The Prevention Of WEight Regain in diabetes type 2 (POWER) study: the effectiveness of adding a combined psychological intervention to a very low calorie diet, design and pilot data of a randomized controlled trial. BMC Public Health. 2012 Nov 23;12:1026. doi: 10.1186/1471-2458-12-1026.</citation>
    <PMID>23176668</PMID>
  </reference>
  <results_reference>
    <citation>Browning JD, Baxter J, Satapati S, Burgess SC. The effect of short-term fasting on liver and skeletal muscle lipid, glucose, and energy metabolism in healthy women and men. J Lipid Res. 2012 Mar;53(3):577-86. doi: 10.1194/jlr.P020867. Epub 2011 Dec 3.</citation>
    <PMID>22140269</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2015</study_first_submitted>
  <study_first_submitted_qc>July 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2015</study_first_posted>
  <results_first_submitted>July 21, 2015</results_first_submitted>
  <results_first_submitted_qc>October 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 3, 2015</results_first_posted>
  <last_update_submitted>November 2, 2015</last_update_submitted>
  <last_update_submitted_qc>November 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nazarbayev University Medical Center</investigator_affiliation>
    <investigator_full_name>Kuat Oshakbayev</investigator_full_name>
    <investigator_title>Primary investigator</investigator_title>
  </responsible_party>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Diabetes mellitus,</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Overweight</keyword>
  <keyword>analimentary detoxication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Orlistat</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Conventional Patient Group</title>
          <description>Xenical (Orlistat) 120 mg a day for 6 months with antidiabetes, antihypertensive therapy
Xenical (Orlistat): Xenical (Orlistat) - 120 mg/day, Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day</description>
        </group>
        <group group_id="P2">
          <title>&quot;Analimentary Detoxication&quot;</title>
          <description>Dietary Supplement - Vegetable and salt diet. Weight loss program &quot;Analimentary detoxication&quot;
&quot;Analimentary detoxication&quot;: Vegetable and salt diet</description>
        </group>
        <group group_id="P3">
          <title>Healthy People</title>
          <description>64 healthy people</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="269"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="222"/>
                <participants group_id="P3" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Moved out of area</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused treatment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Conventional Patient Group</title>
          <description>Xenical (Orlistat) 120 mg a day for 6 months with antidiabetes, antihypertensive therapy
Xenical (Orlistat): Xenical (Orlistat) - 120 mg/day, Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day</description>
        </group>
        <group group_id="B2">
          <title>&quot;Analimentary Detoxication&quot;</title>
          <description>Dietary Supplement - Vegetable and salt diet. Weight loss program &quot;Analimentary detoxication&quot;
&quot;Analimentary detoxication&quot;: Vegetable and salt diet</description>
        </group>
        <group group_id="B3">
          <title>Healthy People</title>
          <description>64 healthy people</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="222"/>
            <count group_id="B3" value="64"/>
            <count group_id="B4" value="351"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" spread="13.6"/>
                    <measurement group_id="B2" value="47.4" spread="12.8"/>
                    <measurement group_id="B3" value="47.7" spread="12.3"/>
                    <measurement group_id="B4" value="47.3" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Blood Glucose Level</title>
        <description>Fasting blood glucose (FBG) (mmole/L) and Two-hour postprandial glucose (THPG) (mmole/L) were measured.</description>
        <time_frame>up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional Patient Group</title>
            <description>Xenical (Orlistat) 120 mg a day for 6 months with antidiabetes, antihypertensive therapy
Xenical (Orlistat): Xenical (Orlistat) - 120 mg/day, Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day</description>
          </group>
          <group group_id="O2">
            <title>&quot;Analimentary Detoxication&quot; Weight Loss</title>
            <description>Dietary Supplement - Vegetable and salt diet. Weight loss program &quot;Analimentary detoxication&quot;
&quot;Analimentary detoxication&quot;: Vegetable and salt diet</description>
          </group>
          <group group_id="O3">
            <title>Healthy People</title>
            <description>64 healthy people</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Glucose Level</title>
          <description>Fasting blood glucose (FBG) (mmole/L) and Two-hour postprandial glucose (THPG) (mmole/L) were measured.</description>
          <units>mmole/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasting blood glucose level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" spread="0.46"/>
                    <measurement group_id="O2" value="6.43" spread="0.36"/>
                    <measurement group_id="O3" value="4.58" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two-hour postprandial glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="0.28"/>
                    <measurement group_id="O2" value="14.6" spread="0.28"/>
                    <measurement group_id="O3" value="5.3" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Systolic/ Diastolic Blood Pressures (mm Hg)</title>
        <description>Systolic and Diastolic Blood Pressures (mm Hg) was measured by manual/automatic tonometery</description>
        <time_frame>up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional Patient Group</title>
            <description>Xenical (Orlistat) 120 mg a day for 6 months with antidiabetes, antihypertensive therapy
Xenical (Orlistat): Xenical (Orlistat) - 120 mg/day, Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day</description>
          </group>
          <group group_id="O2">
            <title>&quot;Analimentary Detoxication&quot; Weight Loss</title>
            <description>Dietary Supplement - Vegetable and salt diet. Weight loss program &quot;Analimentary detoxication&quot;
&quot;Analimentary detoxication&quot;: Vegetable and salt diet</description>
          </group>
          <group group_id="O3">
            <title>Healthy People</title>
            <description>64 healthy people</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic/ Diastolic Blood Pressures (mm Hg)</title>
          <description>Systolic and Diastolic Blood Pressures (mm Hg) was measured by manual/automatic tonometery</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.2" spread="1.1"/>
                    <measurement group_id="O2" value="152.1" spread="1.1"/>
                    <measurement group_id="O3" value="121.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" spread="0.7"/>
                    <measurement group_id="O2" value="96.9" spread="0.8"/>
                    <measurement group_id="O3" value="79.9" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Profile</title>
        <description>Blood sample for lipid profile (Cholesterol in mmole/L, High-density Lipoproteids in mmole/L, Triglycerides in mmole/L) was measured</description>
        <time_frame>up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional Patient Group</title>
            <description>Xenical (Orlistat) 120 mg a day for 6 months with antidiabetes, antihypertensive therapy
Xenical (Orlistat): Xenical (Orlistat) - 120 mg/day, Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day</description>
          </group>
          <group group_id="O2">
            <title>&quot;Analimentary Detoxication&quot; Weight Loss</title>
            <description>Dietary Supplement - Vegetable and salt diet. Weight loss program &quot;Analimentary detoxication&quot;
&quot;Analimentary detoxication&quot;: Vegetable and salt diet</description>
          </group>
          <group group_id="O3">
            <title>Healthy People</title>
            <description>64 healthy people</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Profile</title>
          <description>Blood sample for lipid profile (Cholesterol in mmole/L, High-density Lipoproteids in mmole/L, Triglycerides in mmole/L) was measured</description>
          <units>mmole/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.22" spread="0.18"/>
                    <measurement group_id="O2" value="5.35" spread="0.17"/>
                    <measurement group_id="O3" value="4.9" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-density Lipoproteids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.007"/>
                    <measurement group_id="O2" value="0.75" spread="0.004"/>
                    <measurement group_id="O3" value="1.22" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.18"/>
                    <measurement group_id="O2" value="2.2" spread="0.12"/>
                    <measurement group_id="O3" value="1.4" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunoassay Hormones in Blood</title>
        <description>Immunoassay Insulin in the blood (in nU/L) was investigated</description>
        <time_frame>up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional Patient Group</title>
            <description>Xenical (Orlistat) 120 mg a day for 6 months with antidiabetes, antihypertensive therapy
Xenical (Orlistat): Xenical (Orlistat) - 120 mg/day, Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day</description>
          </group>
          <group group_id="O2">
            <title>&quot;Analimentary Detoxication&quot;</title>
            <description>Dietary Supplement - Vegetable and salt diet. Weight loss program &quot;Analimentary detoxication&quot;
&quot;Analimentary detoxication&quot;: Vegetable and salt diet</description>
          </group>
          <group group_id="O3">
            <title>Healthy People</title>
            <description>64 healthy people</description>
          </group>
        </group_list>
        <measure>
          <title>Immunoassay Hormones in Blood</title>
          <description>Immunoassay Insulin in the blood (in nU/L) was investigated</description>
          <units>nU/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" spread="1.1"/>
                    <measurement group_id="O2" value="23.2" spread="1.0"/>
                    <measurement group_id="O3" value="6.5" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunoassay Cortisole in Blood</title>
        <description>Immunoassay Cortisole in the blood (nmole/L) was measured</description>
        <time_frame>up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional Patient Group</title>
            <description>Xenical (Orlistat) 120 mg a day for 6 months with antidiabetes, antihypertensive therapy
Xenical (Orlistat): Xenical (Orlistat) - 120 mg/day, Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day</description>
          </group>
          <group group_id="O2">
            <title>&quot;Analimentary Detoxication&quot;</title>
            <description>Dietary Supplement - Vegetable and salt diet. Weight loss program &quot;Analimentary detoxication&quot;
&quot;Analimentary detoxication&quot;: Vegetable and salt diet</description>
          </group>
          <group group_id="O3">
            <title>Healthy People</title>
            <description>64 healthy people</description>
          </group>
        </group_list>
        <measure>
          <title>Immunoassay Cortisole in Blood</title>
          <description>Immunoassay Cortisole in the blood (nmole/L) was measured</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="743.8" spread="6.9"/>
                    <measurement group_id="O2" value="751.2" spread="6.7"/>
                    <measurement group_id="O3" value="445.3" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Conventional Patient Group</title>
          <description>Xenical (Orlistat) 120 mg a day for 6 months with antidiabetes, antihypertensive therapy
Xenical (Orlistat): Xenical (Orlistat) - 120 mg/day, Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day</description>
        </group>
        <group group_id="E2">
          <title>&quot;Analimentary Detoxication&quot;</title>
          <description>Dietary Supplement - Vegetable and salt diet. Weight loss program &quot;Analimentary detoxication&quot;
&quot;Analimentary detoxication&quot;: Vegetable and salt diet</description>
        </group>
        <group group_id="E3">
          <title>Healthy People</title>
          <description>64 healthy people</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Indigestions</sub_title>
                <description>diarrhea, itching, gastritis</description>
                <counts group_id="E1" events="78" subjects_affected="29" subjects_at_risk="65"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="222"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="164" subjects_affected="42" subjects_at_risk="65"/>
                <counts group_id="E2" events="52" subjects_affected="26" subjects_at_risk="222"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>hypertermia</sub_title>
                <counts group_id="E1" events="160" subjects_affected="40" subjects_at_risk="65"/>
                <counts group_id="E2" events="124" subjects_affected="62" subjects_at_risk="222"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We acknowledge the randomized clinical trial have not a large sample size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kuat Oshakbayev</name_or_title>
      <organization>Republican Scientific Center for Emergency care at Nazarbayev University</organization>
      <phone>+77013999141</phone>
      <email>okp.kuat@mail.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

